EMAIL THIS PAGE TO A FRIEND

Journal of pharmaceutical sciences

Preparation and evaluation of high dispersion stable nanocrystal formulation of poorly water-soluble compounds by using povacoat.


PMID 25209659

Abstract

In this study, we reported the application of Povacoat®, a hydrophilic polyvinylalcohol copolymer, as a dispersion stabilizer of nanoparticles of poorly water-soluble compounds. In addition, the influence of aggregation of the nanoparticles on their solubility and oral absorption was studied. Griseofulvin (GF) was used as a model compound with poor water solubility and was milled to nanoparticles by wet bead milling. The dispersion stability of GF milled with Povacoat® or the generally used polymers (polyvinylalcohol, hydroxypropylcellulose SSL, and polyvinylpyrrolidone K30) was compared. Milled GF suspended in Povacoat® aqueous solution with D-mannitol, added to improve the disintegration rate of freeze-dried GF, exhibited high dispersion stability without aggregation (D90 = ca. 0.220 μm), whereas milled GF suspended in aqueous solutions of the other polymers aggregated (D90 > 5 μm). Milled GF with Povacoat® showed improved aqueous solubility and bioavailability compared with the other polymers. The aggregation of nanoparticles had significant impact on the solubility and bioavailability of GF. Povacoat® also prevented the aggregation of the various milled poorly water-soluble compounds (hydrochlorothiazide and tolbutamide, etc.) more effectively than the other polymers. These results showed that Povacoat® could have wide applicability to the development of nanoformulations of poorly water-soluble compounds.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

D4007
5,5-Diphenylhydantoin, ≥99%
C15H12N2O2
A0220000
Aciclovir, European Pharmacopoeia (EP) Reference Standard
C8H11N5O3
Y0001271
Aciclovir for peak identification 1, European Pharmacopoeia (EP) Reference Standard
C8H11N5O3
Y0001269
Aciclovir for peak identification 2, European Pharmacopoeia (EP) Reference Standard
C8H11N5O3
Y0001264
Aciclovir for system suitability, European Pharmacopoeia (EP) Reference Standard
C8H11N5O3
A4669
Acycloguanosine, ≥99% (HPLC), powder
C8H11N5O3
1012065
Acyclovir, United States Pharmacopeia (USP) Reference Standard
C8H11N5O3
PHR1254
Acyclovir, Pharmaceutical Secondary Standard; Certified Reference Material
C8H11N5O3
G4753
Griseofulvin, from Penicillium griseofulvum, 97.0-102.0%
C17H17ClO6
46309
Griseofulvin, VETRANAL, analytical standard
C17H17ClO6
G0600000
Griseofulvin, European Pharmacopoeia (EP) Reference Standard
C17H17ClO6
1299007
Griseofulvin, United States Pharmacopeia (USP) Reference Standard
C17H17ClO6
PHR1534
Griseofulvin, Pharmaceutical Secondary Standard; Certified Reference Material
C17H17ClO6
1299200
Griseofulvin Permeability Diameter, United States Pharmacopeia (USP) Reference Standard
C17H17ClO6
H4759
Hydrochlorothiazide, crystalline
C7H8ClN3O4S2
H2910
Hydrochlorothiazide, meets USP testing specifications
C7H8ClN3O4S2
1314009
Hydrochlorothiazide, United States Pharmacopeia (USP) Reference Standard
C7H8ClN3O4S2
PHR1032
Hydrochlorothiazide, Pharmaceutical Secondary Standard; Certified Reference Material
C7H8ClN3O4S2
H1200000
Hydrochlorothiazide, European Pharmacopoeia (EP) Reference Standard
C7H8ClN3O4S2
Y0001494
Hydrochlorothiazide for peak identification, European Pharmacopoeia (EP) Reference Standard
C7H8ClN3O4S2
46482
Naproxen, VETRANAL, analytical standard
C14H14O3
PHR1040
Naproxen, Pharmaceutical Secondary Standard; Certified Reference Material
C14H14O3
N0250000
Naproxen, European Pharmacopoeia (EP) Reference Standard
C14H14O3
1457301
Naproxen, United States Pharmacopeia (USP) Reference Standard
C14H14O3
PHR1139
Phenytoin, Pharmaceutical Secondary Standard; Certified Reference Material
C15H12N2O2
1535008
Phenytoin, United States Pharmacopeia (USP) Reference Standard
C15H12N2O2
P1290000
Phenytoin, European Pharmacopoeia (EP) Reference Standard
C15H12N2O2
Y0001167
Phenytoin for system suitability, European Pharmacopoeia (EP) Reference Standard
C15H12N2O2
P5654
Piroxicam, ≥98% (TLC)
C15H13N3O4S
P0847
Piroxicam, meets USP testing specifications
C15H13N3O4S